Mediatensyl Lp

Urapidil, the active ingredient in Mediatensyl Lp, is a Alpha-1 adrenergic antagonist presented as a tablet for oral use. It treats hypertension in adult patients by lowering systemic blood pressure.

GNH USA supplies Mediatensyl Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Urapidil is used to manage high blood pressure conditions by targeting peripheral vascular tone.

- Essential hypertension: reduces elevated blood pressure through vasodilation. - Secondary hypertension: helps control blood pressure when caused by underlying disorders. - Hypertensive emergencies: provides rapid blood pressure reduction when administered under medical supervision.

Urapidil may be associated with a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness - Headache - Nausea or upset stomach - Flushing of the skin - Mild hypotension - Transient tachycardia

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Cardiac arrhythmias - Hepatic enzyme elevation - Allergic skin reactions such as rash or urticaria

Before initiating therapy, several safety considerations should be observed.

- Blood pressure monitoring: check regularly to avoid excessive drops. - Renal function assessment: adjust use in patients with impaired clearance. - Hepatic impairment: use cautiously, monitor liver enzymes. - Elderly patients: start at lower doses and watch for orthostatic effects. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture.

Urapidil can interact with other medicines that affect blood pressure or metabolic pathways.

Major Interactions (Avoid): - Concurrent use with other potent antihypertensives (e.g., intravenous nitroprusside) may cause severe hypotension. - Combination with monoamine oxidase inhibitors can lead to unpredictable vascular responses.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt compensatory heart rate increase. - Diuretics: additive blood pressure‑lowering effect, require monitoring. - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels of Urapidil. - NSAIDs: can reduce antihypertensive efficacy.